13F Holdings
中文EN

SXTP 60 DEGREES PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1946563 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.8%
TTM net income YoY-4.7%
TTM EPS YoY95.7%
Revenue 3-yr CAGR115.4%
Net income 3-yr CAGR—

Margins

Gross margin24.1%
Operating margin-971.9%
Net margin-921.0%
FCF margin-906.9%
EBITDA margin-964.6%

Returns

ROE-316.7%
ROA-170.7%
ROIC (approx.)-1,197.4%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets75.6%
Debt / equity0.18x
Current ratio1.17x
Interest coverage-1,207.18x

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue12.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$1.01M$607,574$253,573$223,208
Cost of revenue$781,695$384,765$474,550$432,370
Gross profit$223,776$222,809-$220,977-$209,162
R&D expense$2.11M$4.99M$691,770$525,563
SG&A expense$6.28M$5.03M$4.24M$1.30M
Operating income-$7.76M-$9.72M-$5.15M-$1.75M
Interest expense$7,805$7,912$2.29M$3.99M
Pretax income-$7.37M-$7.96M-$3.81M-$6.18M
Income tax$0$0$250$500
Net income-$7.37M-$7.95M-$3.77M-$6.18M
EBITDA-$7.72M-$9.70M-$5.13M-$1.72M
EPS (basic)-11.73-74.17-59.18-2.61
EPS (diluted)-11.73-74.17-59.18-2.61
Weighted avg. shares (diluted)670,211113,66566,3142.37M
Banking
Net interest income——$1.34M-$4.43M
Balance sheet
Cash & equivalents$1.51M$1.66M$2.14M$264,865
Short-term investments$1.24M$1.73M——
Receivables$509,644$486,748$231,332$45,965
Inventory$656,924$442,764$466,169$518,578
Current assets$4.90M$5.39M$7.24M$1.10M
PP&E, net$246,365$149,808$57,761$21,300
Intangibles$224,361$157,084$227,258$164,255
Total assets$5.37M$5.76M$7.78M$1.30M
Current liabilities$1.85M$1.66M$2.84M$23.92M
Short-term debt$11,517$8,772$8,772—
Long-term debt$144,003$147,119$150,000$1.11M
Total debt$155,520$155,891$158,772$1.11M
Total liabilities$1.99M$1.80M$2.99M$25.45M
Shareholders' equity$3.46M$4.04M$4.87M-$23.58M
Net debt-$1.35M-$1.50M-$1.98M$844,918
Shares outstanding1.16M141,74996,847—
Cash flow statement
Operating cash flow-$6.85M-$5.65M-$4.54M-$1.01M
Capital expenditure$139,881$103,773$57,623—
Free cash flow-$6.99M-$5.75M-$4.60M—
Investing cash flow$254,916-$1.89M-$115,888-$60,133
Financing cash flow$6.44M$7.05M$6.47M$1.22M
Depreciation & amortization$43,324$11,726$21,162$27,648
Stock-based compensation$456,344$3.61M$212,605$0

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.